Effects of Pyrazinoylguanidine on the Glucose-Fatty Acid Cycle in Normal Subjects and Patients with Non-Insulin-Dependent Diabetes Mellitus
Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose‐fatty...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacology 1993-09, Vol.33 (9), p.823-831 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 831 |
|---|---|
| container_issue | 9 |
| container_start_page | 823 |
| container_title | Journal of clinical pharmacology |
| container_volume | 33 |
| creator | Vesell, Elliot S. Chambers, Charles E. Passananti, G. Thomas Demers, Laurence M. Beyer Jr, Karl H. |
| description | Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose‐fatty acid cycle toward a more normal level in NIDDM patients and in non‐diabetic subjects maintained on HCTZ. Despite maintenance of these NIDDM patients on their current antihypertensive medication, PZG reduced further their systolic and diastolic pressures. PZG was well tolerated by both normal and NIDDM patients. |
| doi_str_mv | 10.1002/j.1552-4604.1993.tb01958.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76058528</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76058528</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4388-a759e0e4c02b5a11e2897d5be0e051b46aa8f48a846a99d8c7ba923e530942443</originalsourceid><addsrcrecordid>eNqVUd1u0zAYjRBolMEjIFkIcZdgO3Zic8XUbe2mMYr4vbMc5wtzlzoldrSGV-ClcWjVe6782ed8x0fnJMkrgjOCMX27zgjnNGUFZhmRMs9ChYnkIts9SmZH6HEyw1iSlJYYP02eeb_GmBSMk5PkRFBaslLOkj8XTQMmeNQ1aDX2-rd13dj-HLSztXWAOofCHaBFO5jOQ3qpQxjRmbE1mo-mBWQduu36jW7R56Fa_1PSrkYrHSy4eHmw4S4yXHrl_NBal57DFlwdMXRudQUBPPoAbWvD4J8nTxrdenhxOE-Tr5cXX-bL9Obj4mp-dpMalguR6pJLwMAMphXXhAAVsqx5Fd8wJxUrtBYNE1rEScpamLLSkubAcywZZSw_Td7sdbd992sAH9TGehNNaAfd4FVZYC44FZH4bk80fed9D43a9naj-1ERrKYm1FpNcaspbjU1oQ5NqF1cfnn4Zag2UB9XD9FH_PUB197otum1M9YfaUySQpaTh_d72oNtYfwPA-p6vlpOY5RI9xLWB9gdJXR_r4oyL7n6frtQP66_fYq2lirP_wICtLaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76058528</pqid></control><display><type>article</type><title>Effects of Pyrazinoylguanidine on the Glucose-Fatty Acid Cycle in Normal Subjects and Patients with Non-Insulin-Dependent Diabetes Mellitus</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Vesell, Elliot S. ; Chambers, Charles E. ; Passananti, G. Thomas ; Demers, Laurence M. ; Beyer Jr, Karl H.</creator><creatorcontrib>Vesell, Elliot S. ; Chambers, Charles E. ; Passananti, G. Thomas ; Demers, Laurence M. ; Beyer Jr, Karl H.</creatorcontrib><description>Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose‐fatty acid cycle toward a more normal level in NIDDM patients and in non‐diabetic subjects maintained on HCTZ. Despite maintenance of these NIDDM patients on their current antihypertensive medication, PZG reduced further their systolic and diastolic pressures. PZG was well tolerated by both normal and NIDDM patients.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1002/j.1552-4604.1993.tb01958.x</identifier><identifier>PMID: 8227479</identifier><identifier>CODEN: JCPCBR</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Blood Glucose - metabolism ; Diabetes Mellitus, Type 2 - metabolism ; Down-Regulation ; Fatty Acids - metabolism ; Female ; General and cellular metabolism. Vitamins ; Glucose Tolerance Test ; Guanidines - pharmacology ; Humans ; Hydrochlorothiazide - pharmacology ; Insulin - blood ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pyrazines - pharmacology ; Uremia - drug therapy</subject><ispartof>Journal of clinical pharmacology, 1993-09, Vol.33 (9), p.823-831</ispartof><rights>1993 American College of Clinical Pharmacology</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4388-a759e0e4c02b5a11e2897d5be0e051b46aa8f48a846a99d8c7ba923e530942443</citedby><cites>FETCH-LOGICAL-c4388-a759e0e4c02b5a11e2897d5be0e051b46aa8f48a846a99d8c7ba923e530942443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fj.1552-4604.1993.tb01958.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fj.1552-4604.1993.tb01958.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4916978$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8227479$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vesell, Elliot S.</creatorcontrib><creatorcontrib>Chambers, Charles E.</creatorcontrib><creatorcontrib>Passananti, G. Thomas</creatorcontrib><creatorcontrib>Demers, Laurence M.</creatorcontrib><creatorcontrib>Beyer Jr, Karl H.</creatorcontrib><title>Effects of Pyrazinoylguanidine on the Glucose-Fatty Acid Cycle in Normal Subjects and Patients with Non-Insulin-Dependent Diabetes Mellitus</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose‐fatty acid cycle toward a more normal level in NIDDM patients and in non‐diabetic subjects maintained on HCTZ. Despite maintenance of these NIDDM patients on their current antihypertensive medication, PZG reduced further their systolic and diastolic pressures. PZG was well tolerated by both normal and NIDDM patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - metabolism</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Down-Regulation</subject><subject>Fatty Acids - metabolism</subject><subject>Female</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Glucose Tolerance Test</subject><subject>Guanidines - pharmacology</subject><subject>Humans</subject><subject>Hydrochlorothiazide - pharmacology</subject><subject>Insulin - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrazines - pharmacology</subject><subject>Uremia - drug therapy</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVUd1u0zAYjRBolMEjIFkIcZdgO3Zic8XUbe2mMYr4vbMc5wtzlzoldrSGV-ClcWjVe6782ed8x0fnJMkrgjOCMX27zgjnNGUFZhmRMs9ChYnkIts9SmZH6HEyw1iSlJYYP02eeb_GmBSMk5PkRFBaslLOkj8XTQMmeNQ1aDX2-rd13dj-HLSztXWAOofCHaBFO5jOQ3qpQxjRmbE1mo-mBWQduu36jW7R56Fa_1PSrkYrHSy4eHmw4S4yXHrl_NBal57DFlwdMXRudQUBPPoAbWvD4J8nTxrdenhxOE-Tr5cXX-bL9Obj4mp-dpMalguR6pJLwMAMphXXhAAVsqx5Fd8wJxUrtBYNE1rEScpamLLSkubAcywZZSw_Td7sdbd992sAH9TGehNNaAfd4FVZYC44FZH4bk80fed9D43a9naj-1ERrKYm1FpNcaspbjU1oQ5NqF1cfnn4Zag2UB9XD9FH_PUB197otum1M9YfaUySQpaTh_d72oNtYfwPA-p6vlpOY5RI9xLWB9gdJXR_r4oyL7n6frtQP66_fYq2lirP_wICtLaQ</recordid><startdate>199309</startdate><enddate>199309</enddate><creator>Vesell, Elliot S.</creator><creator>Chambers, Charles E.</creator><creator>Passananti, G. Thomas</creator><creator>Demers, Laurence M.</creator><creator>Beyer Jr, Karl H.</creator><general>Blackwell Publishing Ltd</general><general>Sage Science</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199309</creationdate><title>Effects of Pyrazinoylguanidine on the Glucose-Fatty Acid Cycle in Normal Subjects and Patients with Non-Insulin-Dependent Diabetes Mellitus</title><author>Vesell, Elliot S. ; Chambers, Charles E. ; Passananti, G. Thomas ; Demers, Laurence M. ; Beyer Jr, Karl H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4388-a759e0e4c02b5a11e2897d5be0e051b46aa8f48a846a99d8c7ba923e530942443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - metabolism</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Down-Regulation</topic><topic>Fatty Acids - metabolism</topic><topic>Female</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Glucose Tolerance Test</topic><topic>Guanidines - pharmacology</topic><topic>Humans</topic><topic>Hydrochlorothiazide - pharmacology</topic><topic>Insulin - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrazines - pharmacology</topic><topic>Uremia - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vesell, Elliot S.</creatorcontrib><creatorcontrib>Chambers, Charles E.</creatorcontrib><creatorcontrib>Passananti, G. Thomas</creatorcontrib><creatorcontrib>Demers, Laurence M.</creatorcontrib><creatorcontrib>Beyer Jr, Karl H.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vesell, Elliot S.</au><au>Chambers, Charles E.</au><au>Passananti, G. Thomas</au><au>Demers, Laurence M.</au><au>Beyer Jr, Karl H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Pyrazinoylguanidine on the Glucose-Fatty Acid Cycle in Normal Subjects and Patients with Non-Insulin-Dependent Diabetes Mellitus</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>1993-09</date><risdate>1993</risdate><volume>33</volume><issue>9</issue><spage>823</spage><epage>831</epage><pages>823-831</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><coden>JCPCBR</coden><abstract>Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose‐fatty acid cycle toward a more normal level in NIDDM patients and in non‐diabetic subjects maintained on HCTZ. Despite maintenance of these NIDDM patients on their current antihypertensive medication, PZG reduced further their systolic and diastolic pressures. PZG was well tolerated by both normal and NIDDM patients.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>8227479</pmid><doi>10.1002/j.1552-4604.1993.tb01958.x</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-2700 |
| ispartof | Journal of clinical pharmacology, 1993-09, Vol.33 (9), p.823-831 |
| issn | 0091-2700 1552-4604 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76058528 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Biological and medical sciences Blood Glucose - metabolism Diabetes Mellitus, Type 2 - metabolism Down-Regulation Fatty Acids - metabolism Female General and cellular metabolism. Vitamins Glucose Tolerance Test Guanidines - pharmacology Humans Hydrochlorothiazide - pharmacology Insulin - blood Male Medical sciences Middle Aged Pharmacology. Drug treatments Pyrazines - pharmacology Uremia - drug therapy |
| title | Effects of Pyrazinoylguanidine on the Glucose-Fatty Acid Cycle in Normal Subjects and Patients with Non-Insulin-Dependent Diabetes Mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T16%3A26%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Pyrazinoylguanidine%20on%20the%20Glucose-Fatty%20Acid%20Cycle%20in%20Normal%20Subjects%20and%20Patients%20with%20Non-Insulin-Dependent%20Diabetes%20Mellitus&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Vesell,%20Elliot%20S.&rft.date=1993-09&rft.volume=33&rft.issue=9&rft.spage=823&rft.epage=831&rft.pages=823-831&rft.issn=0091-2700&rft.eissn=1552-4604&rft.coden=JCPCBR&rft_id=info:doi/10.1002/j.1552-4604.1993.tb01958.x&rft_dat=%3Cproquest_cross%3E76058528%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76058528&rft_id=info:pmid/8227479&rfr_iscdi=true |